The 36-month beta value for GDTC is also noteworthy at 0.53. There are mixed opinions on the stock, with 1 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for GDTC is 4.73M, and at present, short sellers hold a 2.51% of that float. The average trading volume of GDTC on October 24, 2024 was 10.67K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
GDTC) stock’s latest price update
The stock of CytoMed Therapeutics Ltd (NASDAQ: GDTC) has increased by 12.99 when compared to last closing price of 2.54.Despite this, the company has seen a gain of 37.98% in its stock price over the last five trading days. globenewswire.com reported 2024-07-17 that Another Patent Granted for CytoMed’s Allogeneic Induced Pluripotent Stem Cell (“iPSC”)-derived Hybrid Gamma Delta Natural Killer T (γδ NKT) cells technology Another Patent Granted for CytoMed’s Allogeneic Induced Pluripotent Stem Cell (“iPSC”)-derived Hybrid Gamma Delta Natural Killer T (γδ NKT) cells technology
GDTC’s Market Performance
CytoMed Therapeutics Ltd (GDTC) has experienced a 37.98% rise in stock performance for the past week, with a 96.58% rise in the past month, and a 33.49% rise in the past quarter. The volatility ratio for the week is 15.12%, and the volatility levels for the past 30 days are at 10.44% for GDTC. The simple moving average for the past 20 days is 42.74% for GDTC’s stock, with a 26.50% simple moving average for the past 200 days.
GDTC Trading at 64.33% from the 50-Day Moving Average
After a stumble in the market that brought GDTC to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -47.82% of loss for the given period.
Volatility was left at 10.44%, however, over the last 30 days, the volatility rate increased by 15.12%, as shares surge +95.24% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +61.24% upper at present.
During the last 5 trading sessions, GDTC rose by +37.98%, which changed the moving average for the period of 200-days by -44.81% in comparison to the 20-day moving average, which settled at $2.01. In addition, CytoMed Therapeutics Ltd saw -41.43% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for GDTC
Current profitability levels for the company are sitting at:
- -14.39 for the present operating margin
- -0.02 for the gross margin
The net margin for CytoMed Therapeutics Ltd stands at -14.34. The total capital return value is set at -0.34. Equity return is now at value -26.36, with -24.78 for asset returns.
Based on CytoMed Therapeutics Ltd (GDTC), the company’s capital structure generated 0.04 points at debt to capital in total, while cash flow to debt ratio is standing at -7.72. The debt to equity ratio resting at 0.04. The interest coverage ratio of the stock is -85.74.
Currently, EBITDA for the company is -2.62 million with net debt to EBITDA at 2.93. When we switch over and look at the enterprise to sales, we see a ratio of 90.5. The receivables turnover for the company is 1.33for trailing twelve months and the total asset turnover is 0.02. The liquidity ratio also appears to be rather interesting for investors as it stands at 21.53.
Conclusion
In summary, CytoMed Therapeutics Ltd (GDTC) has had a mixed performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
